AstraZeneca: TAGRISSO achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial

Treatment with adjuvant TAGRISSO reduced the risk of death by more than half Positive results from the ADAURA Phase III trial showed AstraZeneca's TAGRISSO (osimertinib) demonstrated a statistically

Related Keywords

United States ,Cambridge ,Cambridgeshire ,United Kingdom ,American ,America ,Chelsea Ford ,Le Chevalier ,Daiichi Sankyo ,Brendan Mcevoy ,Lung Ambition Alliance ,World Health Organisation ,Archives Pathology Lab ,Astrazeneca ,Lungevity Foundation ,Data Monitoring Committee ,International Agency For Research On Cancer ,American Society Of Clinical Oncology ,Collaborative Group ,Plenary Session ,Clinical Oncology ,Annual Meeting ,Prescribing Information ,Patient Information ,South America ,Independent Data Monitoring Committee ,Rare Diseases ,Renal Metabolism ,International Agency ,Lung Fact ,Accessed March ,Cancer Biomarkers ,Present Status ,Resectable Non Small Cell Lung Cancer ,Cancer Staging Project ,Adjuvant Cisplatin Evaluation ,Pooled Analysis ,Tagrisso ,Chieved ,Unprecedented ,Survival ,Early ,Stage ,Egfr ,Mutated ,Young ,Dancer ,Patients ,Live ,Five ,Tears ,Daura ,Hase ,Trial ,